Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Metaglip · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Glipizide and Metformin HCl Tablets 5 mg/500 mg |
| 2 | ACTIVE_COMPARATOR | Metaglip® Tablets 5 mg/500 mg |
| Name | Type | Description |
|---|---|---|
| Glipizide and Metformin HCl Tablets 5 mg/500 mg | DRUG | 5/500mg, single dose fed |
| Metaglip® Tablets 5 mg/500 mg | DRUG | 5/500mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older 2. Sex: Male and/or non-pregnant, non-lactating female a. Women of childbearing potential must have a negative serum (β-HCG) pregnancy test performed within 21 days prior to the start of the study and on the evening prior to each dose administration. I...
Metaglip is a small molecule drug being developed by Viatris Inc. (VTRS). It is currently in Phase 1 clinical development. Metaglip is being studied in healthy volunteers, and it is an investigational drug, not yet approved by the FDA.
Metaglip is being studied for use in healthy volunteers. The clinical trials for Metaglip are food and fasting studies, which are typically conducted to assess the pharmacokinetics of a drug. The drug is currently in Phase 1 development.
Metaglip is being developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the company responsible for the clinical development of Metaglip.
Metaglip is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA. The drug is being studied in healthy volunteers in two completed Phase 1 trials.
Metaglip has been studied in two completed Phase 1 clinical trials. The first trial, NCT00648505, is a food study comparing Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip Tablets 5 mg/500 mg. The second trial, NCT00649454, is a fasting study with the same comparison. Both trials enrolled 36 healthy volunteers each.